Human Genome Epidemiology Literature Finder
Records 1 - 13 (of 13 Records) |
Query Trace: Fatigue and BRAF[original query] |
---|
Phase II trial of sorafenib in metastatic thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Apr 27 (10): 1675-84. Kloos Richard T, Ringel Matthew D, Knopp Michael V, Hall Nathan C, King Mark, Stevens Robert, Liang Jiachao, Wakely Paul E, Vasko Vasyl V, Saji Motoyasu, Rittenberry Jennifer, Wei Lai, Arbogast Daria, Collamore Minden, Wright John J, Grever Michael, Shah Manisha |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England) 2012 Jul 380 (9839): 358-65. Hauschild Axel, Grob Jean-Jacques, Demidov Lev V, Jouary Thomas, Gutzmer Ralf, Millward Michael, Rutkowski Piotr, Blank Christian U, Miller Wilson H, Kaempgen Eckhart, Martín-Algarra Salvador, Karaszewska Boguslawa, Mauch Cornelia, Chiarion-Sileni Vanna, Martin Anne-Marie, Swann Suzanne, Haney Patricia, Mirakhur Beloo, Guckert Mary E, Goodman Vicki, Chapman Paul |
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Apr 18 (7): 2056-65. Hayes D Neil, Lucas Amy S, Tanvetyanon Tawee, Krzyzanowska Monika K, Chung Christine H, Murphy Barbara A, Gilbert Jill, Mehra Ranee, Moore Dominic T, Sheikh Arif, Hoskins Janelle, Hayward Michele C, Zhao Ni, O'Connor Wendi, Weck Karen E, Cohen Roger B, Cohen Ezra E |
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO open 2016 1 (6): e000086. Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro A R, Rachiglio A M, Lambiase M, Latiano T P, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli Vincenzo, Nasti Guglielmo, Nappi Anna, Botti Gerardo, Tatangelo F, Chicchinelli Nicoletta, Montrone Mirko, Sebastio Annamaria, Guarino Tiziana, Simone Gianni, Graziano Paolo, Chiarazzo Cinzia, Maggio GabrieleDi, Longhitano Laura, Manusia Mario, Cartenì Giacomo, Nappi Oscar, Micheli Pietro, Leo Luigi, Rossi Sabrina, Cassano Alessandra, Tommaselli Eugenio, Giordano Guido, Sponziello Francesco, Marino Antonella, Rinaldi Antonio, Romito Sante, Muda Andrea Onetti, Lorusso Vito, Leo Silvana, Barni Sandro, Grimaldi Giuseppe, Aieta Miche |
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. British journal of cancer 2017 Feb . Bendell Johanna C, Javle Milind, Bekaii-Saab Tanios S, Finn Richard S, Wainberg Zev A, Laheru Daniel A, Weekes Colin D, Tan Benjamin R, Khan Gazala N, Zalupski Mark M, Infante Jeffrey R, Jones Suzanne, Papadopoulos Kyriakos P, Tolcher Anthony W, Chavira Renae E, Christy-Bittel Janna L, Barrett Emma, Patnaik Ami |
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. European journal of cancer (Oxford, England : 1990) 2018 May 97 7-15. Cavalieri S, Perrone F, Miceli R, Ascierto P A, Locati L D, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi |
Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. International journal of cancer 2020 12 . Jensen Benny Vittrup, Schou Jakob V, Yilmaz Mette, Johannesen Helle H, Skougaard Kristin, Linnemann Dorte, Hogdall Estrid V, Larsen Finn O, Johansen Julia S, Pfeiffer Per, Nielsen Dorte |
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO precision oncology 2022 11 6 e2200191. Klute Kelsey A, Rothe Michael, Garrett-Mayer Elizabeth, Mangat Pam K, Nazemzadeh Reza, Yost Kathleen J, Duvivier Herbert L, Ahn Eugene R, Cannon Timothy L, Alese Olatunji B, Krauss John C, Thota Ramya, Calfa Carmen J, Denlinger Crystal S, O'Lone Raegan, Halabi Susan, Grantham Gina N, Schilsky Richard |
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 2023 5 11 (5): . Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouz |
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nature medicine 2023 4 . Subbiah Vivek, Kreitman Robert J, Wainberg Zev A, Gazzah Anas, Lassen Ulrik, Stein Alexander, Wen Patrick Y, Dietrich Sascha, de Jonge Maja J A, Blay Jean-Yves, Italiano Antoine, Yonemori Kan, Cho Daniel C, de Vos Filip Y F L, Moreau Philippe, Fernandez Elena Elez, Schellens Jan H M, Zielinski Christoph C, Redhu Suman, Boran Aislyn, Passos Vanessa Q, Ilankumaran Palanichamy, Bang Yung-J |
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors. Cancer 2023 4 . Mooradian Meghan J, Cleary James M, Giobbie-Hurder Anita, Darville Lancia N F, Parikh Aparna, Buchbinder Elizabeth I, Cohen Justine V, Lawrence Donald P, Shapiro Geoffrey I, Keer Harold, Chen Helen X, Ivy Susan Percy, Smalley Keiran S M, Koomen John M, Sullivan Ryan |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: